Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Foscarnet sodium
Drug ID BADD_D00964
Description An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV.
Indications and Usage For the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and for treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients.
Marketing Status approved
ATC Code J05AD01
DrugBank ID DB00529
KEGG ID D00579
MeSH ID D017245
PubChem ID 44561
TTD Drug ID D0OT0O
NDC Product Code 29902-0018; 76310-024; 61662-0001; 70600-020; 59651-476; 68083-389; 63323-875; 23155-771; 79290-0001; 25021-189
UNII 964YS0OOG1
Synonyms Foscarnet | Phosphonoformic Acid | Foscarnet Trisodium Salt | Foscarnet Calcium (2:3) Salt | Foscarnet Disodium Salt | Foscarnet Magnesium (2:3) Salt | Trisodium Phosphonoformate | Phosphonoformate | Foscarnet Sodium | Foscarnet Trilithium Salt | Foscarnet Tripotassium Salt | Foscarnet Sodium Hexahydrate | Foscavir | Foscarnet Barium (2:3) Salt | Foscarnet Manganese (2+) (2:3) Salt
Chemical Information
Molecular Formula CNa3O5P
CAS Registry Number 63585-09-1
SMILES C(=O)([O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Polyuria20.02.03.002--Not Available
Pruritus23.03.12.001--
Pseudolymphoma01.09.01.016--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.029--Not Available
Rash maculo-papular23.03.13.004--
Rectal haemorrhage24.07.02.018; 07.12.03.001--
Respiratory disorder22.02.07.002--Not Available
Respiratory failure22.02.06.002; 14.01.04.003--
Rhabdomyolysis15.05.05.002--
Rhinitis22.07.03.006; 11.01.13.004--
Sarcoma16.33.01.002; 15.09.03.002--Not Available
Seborrhoea23.02.07.001--Not Available
Seizure17.12.03.001--
Sensory disturbance17.02.07.006--Not Available
Sepsis11.01.11.003--
Sinus tachycardia02.03.03.010--
Sinusitis22.07.03.007; 11.01.13.005--
Skin discolouration23.03.03.005--Not Available
Skin ulcer24.04.03.007; 23.07.03.003--
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome10.01.01.045; 23.03.01.007; 12.03.01.014; 11.07.01.005--
Stridor22.04.02.003--
Stupor17.02.04.007; 19.02.05.004--Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Thrombocytopenia01.08.01.002--Not Available
Thrombosis24.01.01.006--Not Available
Toxic epidermal necrolysis12.03.01.015; 11.07.01.006; 10.01.01.006; 23.03.01.008--
Tremor17.01.06.002--
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages